All Stories

  1. Plasmodium falciparum ring-stage plasticity and drug resistance
  2. Unveiling P. vivax invasion pathways in Duffy-negative individuals
  3. Assessing the histidine-rich protein 2/3 gene deletion in Plasmodium falciparum isolates from Burkina Faso
  4. Malaria in the horn of Africa: The ongoing battle against drug resistance
  5. Prevalence of molecular markers of resistance to sulfadoxine–pyrimethamine before and after community delivery of intermittent preventive treatment of malaria in pregnancy in sub-Saharan Africa: a multi-country evaluation
  6. Increasing Prevalence of Artemisinin-Resistant HRP2-Negative Malaria in Eritrea
  7. Polymorphism analysis of drug resistance markers in Plasmodium falciparum isolates from Benin
  8. Therapeutic efficacy of artesunate–amodiaquine and artemether–lumefantrine for the treatment of uncomplicated falciparum malaria in Chad: clinical and genetic surveillance
  9. Plasmodium falciparum drug resistance-associated mutations in isolates from children living in endemic areas of Burkina Faso
  10. Reduced polymorphism of Plasmodium vivax early transcribed membrane protein (PvETRAMP) 11.2
  11. Duffy-Negative Ethiopians: Potential Hidden Reservoirs of Malaria
  12. Significant number of Plasmodium vivax mono-infections by PCR misidentified as mixed infections (P. vivax/P. falciparum) by microscopy and rapid diagnostic tests: malaria diagnostic challenges in Ethiopia
  13. Ex vivo RSA and pfkelch13 targeted-amplicon deep sequencing reveal parasites susceptibility to artemisinin in Senegal, 2017
  14. Modified Plasmodium falciparum Ring-Stage Survival Assay with ML10 Kinase Inhibitor
  15. Potential hiddenPlasmodium vivaxmalaria reservoirs from low parasitemia Duffy-negative Ethiopians: molecular evidence
  16. Differential transmissibility to Anopheles arabiensis of Plasmodium vivax gametocytes in patients with diverse Duffy blood group genotypes
  17. Ex vivo RSA and Pfkelch13 targeted-amplicon deep sequencing reveal parasites susceptibility to artemisinin in Senegal, 2017
  18. Ring-stage growth arrest: Metabolic basis of artemisinin tolerance in Plasmodium falciparum
  19. Plasmodium vivax blood stage invasion pathways: Contribution of omics technologies in deciphering molecular and cellular mechanisms
  20. Genetic Variants of Glucose-6-Phosphate Dehydrogenase and Their Associated Enzyme Activity: A Systematic Review and Meta-Analysis
  21. Efficacy of three anti-malarial regimens for uncomplicated Plasmodium falciparum malaria in Cambodia, 2009–2011: a randomized controlled trial and brief review
  22. Vivax malaria in Duffy-negative patients shows invariably low asexual parasitaemia: implication towards malaria control in Ethiopia
  23. Human peroxiredoxin 6 is essential for malaria parasites and provides a host-based drug target
  24. Pfkelch13 Plasmodium falciparum Mutations in Huambo, Angola
  25. Artesunate–amodiaquine and artemether–lumefantrine for the treatment of uncomplicated falciparum malaria in Liberia: in vivo efficacy and frequency of molecular markers
  26. Human peroxiredoxin 6 is essential for malaria parasites and provides a host-based drug target
  27. Haematological consequences of acute uncomplicated falciparum malaria: a WorldWide Antimalarial Resistance Network pooled analysis of individual patient data
  28. Repeatability and reproducibility of a handheld quantitative G6PD diagnostic
  29. Efficacy of Three Antimalarial Regimens for Uncomplicated Plasmodium Falciparum Malaria in Cambodia, 2009 – 2011: A Randomized Control Trial
  30. Compensating P. falciparum artemisinin resistance
  31. Hyperendemicity of cysticercosis in Madagascar: Novel insights from school children population-based antigen prevalence study
  32. Development of weight and age-based dosing of daily primaquine for radical cure of vivax malaria
  33. Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria
  34. A genetic intervention
  35. Plasmodium falciparum K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness
  36. Therapeutic efficacy of artesunate-amodiaquine and artemether-lumefantrine and polymorphism in Plasmodium falciparum kelch13-propeller gene in Equatorial Guinea
  37. Author Correction: Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda
  38. Genetic diversity of Plasmodium falciparum populations in three malaria transmission settings in Madagascar
  39. Development of Weight and Age-based Dosing of Daily Primaquine for Radical Cure of Vivax Malaria
  40. Genetic Diversity of Plasmodium Falciparum Populations in three Malaria Transmission Settings in Madagascar
  41. P. falciparum K13 mutations present varying degrees of artemisinin resistance and reduced fitness in African parasites
  42. Genetic Architecture and Dynamics of PfKelch13’s Propeller Domain in Plasmodium Falciparum Clinical Isolates Collected in Senegal.
  43. Anti-malarial efficacy and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017–2018
  44. Plasmodium falciparum K13 mutations in Africa and Asia present varying degrees of artemisinin resistance and an elevated fitness cost in African parasites
  45. Real time, field-deployable whole genome sequencing of malaria parasites using nanopore technology
  46. Knowing the enemy: genetics to track antimalarial resistance
  47. Effect of mass dihydroartemisinin–piperaquine administration in southern Mozambique on the carriage of molecular markers of antimalarial resistance
  48. RIFINing Plasmodium–NK Cell Interaction
  49. Towards harmonization of microscopy methods for malaria clinical research studies
  50. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda
  51. Correction: Quantification of glucose-6-phosphate dehydrogenase activity by spectrophotometry: A systematic review and meta-analysis
  52. Keep the quality high: the benefits of lot testing for the quality control of malaria rapid diagnostic tests
  53. Molecular assessment of kelch13 non-synonymous mutations in Plasmodium falciparum isolates from Central African Republic (2017–2019)
  54. Significant Efficacy of a Single Low Dose of Primaquine Compared to Stand-Alone Artemisinin Combination Therapy in Reducing Gametocyte Carriage in Cambodian Patients with Uncomplicated Multidrug-Resistant Plasmodium falciparum Malaria
  55. Quantification of glucose-6-phosphate dehydrogenase activity by spectrophotometry: A systematic review and meta-analysis
  56. Molecular assessment of kelch13 non-synonymous mutations in Plasmodium falciparum isolates from Central African Republic (2017–2019)
  57. WHO malaria nucleic acid amplification test external quality assessment scheme: results of distribution programmes one to three
  58. Performance of the Access Bio/CareStart rapid diagnostic test for the detection of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis
  59. A review of the WHO malaria rapid diagnostic test product testing programme (2008–2018): performance, procurement and policy
  60. DNA Methylation Bisubstrate Inhibitors Are Fast-Acting Drugs Active against Artemisinin-Resistant Plasmodium falciparum Parasites
  61. Corrigendum to: Hemolytic Dynamics of Weekly Primaquine Antirelapse Therapy Among Cambodians With Acute Plasmodium vivax Malaria With or Without Glucose-6-Phosphate Dehydrogenase Deficiency
  62. Plasmodium falciparum resistance to piperaquine driven by PfCRT
  63. Hemolytic Dynamics of Weekly Primaquine Antirelapse Therapy Among Cambodians With Acute Plasmodium vivax Malaria With or Without Glucose-6-Phosphate Dehydrogenase Deficiency
  64. In vitro activity of ferroquine against artemisinin-based combination therapy (ACT)-resistant Plasmodium falciparum isolates from Cambodia
  65. Accelerated evolution and spread of multidrug-resistant Plasmodium falciparum takes down the latest first-line antimalarial drug in southeast Asia
  66. Improving Methods for Analyzing Antimalarial Drug Efficacy Trials: Molecular Correction Based on Length-Polymorphic Markers msp-1, msp-2, and glurp
  67. Households or Hotspots? Defining Intervention Targets for Malaria Elimination in Ratanakiri Province, Eastern Cambodia
  68. African isolates show a high proportion of multiple copies of the Plasmodium falciparum plasmepsin-2 gene, a piperaquine resistance marker
  69. The tolerability of single low dose primaquine in glucose-6-phosphate deficient and normal falciparum-infected Cambodians
  70. Molecular characterization and mapping of glucose-6-phosphate dehydrogenase (G6PD) mutations in the Greater Mekong Subregion
  71. Plasmodium vivax transcriptomes reveal stage-specific chloroquine response and differential regulation of male and female gametocytes
  72. Lack of quadruple and quintuple mutant alleles associated with sulfadoxine-pyrimethamine resistance in Plasmodium vivax isolates from Brazilian endemic areas
  73. An Update on Artemisinin Resistance
  74. Asymptomatic Plasmodium vivax infections among Duffy-negative population in Kedougou, Senegal
  75. Genetic diversity in two Plasmodium vivax protein ligands for reticulocyte invasion
  76. Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania
  77. Efficacy of artemisinin-based combination therapies and prevalence of molecular markers associated with artemisinin, piperaquine and sulfadoxine-pyrimethamine resistance in Sierra Leone
  78. Emerging Southeast Asian PfCRT mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine
  79. Recrudescence, Reinfection, or Relapse? A More Rigorous Framework to Assess Chloroquine Efficacy forPlasmodium vivaxMalaria
  80. Efficacy of artesunate–amodiaquine in the treatment of falciparum uncomplicated malaria in Madagascar
  81. Importance of household-level risk factors in explaining micro-epidemiology of asymptomatic malaria infections in Ratanakiri Province, Cambodia
  82. Therapeutic and Transmission-Blocking 
Efficacy of Dihydroartemisinin/Piperaquine and Chloroquine against Plasmodium vivax Malaria, Cambodia
  83. Absence of K13 Polymorphism in Plasmodium falciparum from Brazilian Areas Where the Parasite Is Endemic
  84. Targeting a Reticulocyte Binding Protein and Duffy Binding Protein to Inhibit Reticulocyte Invasion by Plasmodium vivax
  85. High proportion of multiple copies of Plasmodium falciparum Plasmepsin-2 gene in African isolates: Is piperaquine resistance emerging in Africa?
  86. In vivo gene expression analyses provide unique insights on P. vivax gametocytogenesis and chloroquine response
  87. Prevalence and risk factors for asymptomatic malaria and genotyping of glucose 6-phosphate (G6PD) deficiencies in a vivax-predominant setting, Lao PDR: implications for sub-national elimination goals
  88. Genetic diversity in two Plasmodium vivax protein ligands for reticulocyte invasion
  89. Plasmepsin II–III copy number accounts for bimodal piperaquine resistance among Cambodian Plasmodium falciparum
  90. A novel field-based molecular assay to detect validated artemisinin-resistant k13 mutants
  91. Multidrug-resistant Plasmodium falciparum malaria in the Greater Mekong subregion
  92. Tools for surveillance of anti-malarial drug resistance: an assessment of the current landscape
  93. Contribution to Malaria Transmission of Symptomatic and Asymptomatic Parasite Carriers in Cambodia
  94. Genomic Analyses Reveal the Common Occurrence and Complexity of Plasmodium vivax Relapses in Cambodia
  95. Closing in on the Reservoir: Proactive Case Detection in High-Risk Groups as a Strategy to Detect Plasmodium falciparum Asymptomatic Carriers in Cambodia
  96. Identification and characterization of areas of high and low risk for asymptomatic malaria infections at sub-village level in Ratanakiri, Cambodia
  97. A Novel Single-Nucleotide Polymorphism Loop Mediated Isothermal Amplification Assay for Detection of Artemisinin-Resistant Plasmodium falciparum Malaria
  98. Functional analysis of Plasmodium falciparum subpopulations associated with artemisinin resistance in Cambodia
  99. Emergence of Plasmodium falciparum triple mutant in Cambodia
  100. Endoperoxide-based compounds: cross-resistance with artemisinins and selection of a Plasmodium falciparum lineage with a K13 non-synonymous polymorphism
  101. Correction to: Prevalence of K13 mutation and Day-3 positive parasitaemia in artemisinin-resistant malaria endemic area of Cambodia: a cross-sectional study
  102. Prevalence of K13 mutation and Day-3 positive parasitaemia in artemisinin-resistant malaria endemic area of Cambodia: a cross-sectional study
  103. Adapting Reactive Case Detection Strategies for falciparum Malaria in a Low-Transmission Area in Cambodia
  104. Characterization of P. vivax blood stage transcriptomes from field isolates reveals similarities among infections and complex gene isoforms
  105. Performance of Rapid Diagnostic Testing in Patients with Suspected Malaria in Cambodia, a Low-Endemicity Country Aiming for Malaria Elimination
  106. The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study
  107. Treatment Failure of Dihydroartemisinin/Piperaquine for Plasmodium falciparum Malaria, Vietnam
  108. Antimalarial Drug Resistance: A Threat to Malaria Elimination
  109. Emergence of Indigenous Artemisinin-Resistant Plasmodium falciparum in Africa
  110. Modelling primaquine-induced haemolysis in G6PD deficiency
  111. A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype–genotype association study
  112. Drug-Resistant Polymorphisms and Copy Numbers inPlasmodium falciparum, Mozambique, 2015
  113. Plasmodium falciparum Resistance to Artemisinin Derivatives and Piperaquine: A Major Challenge for Malaria Elimination in Cambodia
  114. Erratum to: An optimised age-based dosing regimen for single low-dose primaquine for blocking malaria transmission in Cambodia
  115. Plasmodium vivax multidrug resistance-1 gene polymorphism in French Guiana
  116. Serological markers to measure recent changes in malaria at population level in Cambodia
  117. An optimised age-based dosing regimen for single low-dose primaquine for blocking malaria transmission in Cambodia
  118. Optimal health and disease management using spatial uncertainty: a geographic characterization of emergent artemisinin-resistant Plasmodium falciparum distributions in Southeast Asia
  119. Geographical patterns of malaria transmission based on serological markers for falciparum and vivax malaria in Ratanakiri, Cambodia
  120. Plasmodium vivax Malaria in Cambodia
  121. Efficacy of topical mosquito repellent (picaridin) plus long-lasting insecticidal nets versus long-lasting insecticidal nets alone for control of malaria: a cluster randomised controlled trial
  122. Role of K13 Mutations in Artemisinin-Based Combination Therapy
  123. National Malaria Prevalence in Cambodia: Microscopy Versus Polymerase Chain Reaction Estimates
  124. Artemisinin-ResistantPlasmodium falciparumK13 Mutant Alleles, Thailand–Myanmar Border
  125. A Worldwide Map ofPlasmodium falciparumK13-Propeller Polymorphisms
  126. Plasmodium falciparum parasite population structure and gene flow associated to anti-malarial drugs resistance in Cambodia
  127. Low-grade sulfadoxine–pyrimethamine resistance in Plasmodium falciparum parasites from Lubango, Angola
  128. Identification and Characterization of Two Novel RNA Viruses from Anopheles gambiae Species Complex Mosquitoes
  129. Plasmodium copy number variation scan: gene copy numbers evaluation in haploid genomes
  130. Echecs thérapeutiques multiples et successifs chez un patient infecté par Plasmodium falciparum au Cambodge et traité par dihydroartémisinine-pipéraquine
  131. Complexity of Infection and Genetic Diversity in Cambodian Plasmodium vivax
  132. Reactive case-detection of malaria in Pailin Province, Western Cambodia: lessons from a year-long evaluation in a pre-elimination setting
  133. Efficacy and Safety of Pyronaridine-Artesunate for Treatment of Uncomplicated Plasmodium falciparum Malaria in Western Cambodia
  134. Plasmodium vivax mdr1 genotypes in isolates from successfully cured patients living in endemic and non-endemic Brazilian areas
  135. Challenges in Antimalarial Drug Treatment for Vivax Malaria Control
  136. Plasmodium falciparum dihydroartemisinin-piperaquine failures in Cambodia are associated with mutant K13 parasites presenting high survival rates in novel piperaquine in vitro assays: retrospective and prospective investigations
  137. K13-Propeller Polymorphisms in Plasmodium falciparum Isolates from Patients in Mayotte in 2013 and 2014
  138. Novel Cross-Border Approaches to Optimise Identification of Asymptomatic and Artemisinin-Resistant Plasmodium Infection in Mobile Populations Crossing Cambodian Borders
  139. Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient data
  140. Implementation and application of a multiplex assay to detect malaria-specific antibodies: a promising tool for assessing malaria transmission in Southeast Asian pre-elimination areas
  141. Tolerability and safety of weekly primaquine against relapse of Plasmodium vivax in Cambodians with glucose-6-phosphate dehydrogenase deficiency
  142. Plasmodium vivax Diversity and Population Structure across Four Continents
  143. Use of Plasmodium falciparum culture-adapted field isolates for in vitro exflagellation-blocking assay
  144. Evidence of Plasmodium falciparum Malaria Multidrug Resistance to Artemisinin and Piperaquine in Western Cambodia: Dihydroartemisinin-Piperaquine Open-Label Multicenter Clinical Assessment
  145. Towards real-time monitoring of artemisinin resistance
  146. The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data
  147. Malaria rapid diagnostic test as point-of-care test: study protocol for evaluating the VIKIA® Malaria Ag Pf/Pan
  148. Malaria PCR Detection in Cambodian Low-Transmission Settings: Dried Blood Spots Versus Venous Blood Samples
  149. Field Trial Evaluation of the Performances of Point-of-Care Tests for Screening G6PD Deficiency in Cambodia
  150. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates
  151. Histone Methyltransferase Inhibitors Are Orally Bioavailable, Fast-Acting Molecules with Activity against Different Species Causing Malaria in Humans
  152. Reduced Polymorphism in the Kelch Propeller Domain in Plasmodium vivax Isolates from Cambodia
  153. Effects of Mefloquine Use onPlasmodium vivaxMultidrug Resistance
  154. Genetic diversity and population structure of Plasmodium vivax isolates from Sudan, Madagascar, French Guiana and Armenia
  155. Polymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors That Affect Treatment Outcomes for P. falciparum Malaria After Artemether-Lumefantrine and Artesunate-Amodiaquine
  156. Spatial clustering and risk factors of malaria infections in Ratanakiri Province, Cambodia
  157. Independent Emergence of Artemisinin Resistance Mutations Among Plasmodium falciparum in Southeast Asia
  158. Molecular surveillance for artemisinin resistance in Africa
  159. La résistance deP. falciparumà l’artémisinine
  160. Genetic diversity of VAR2CSA ID1-DBL2Xb in worldwide Plasmodium falciparum populations: Impact on vaccine design for placental malaria
  161. Artemisinin resistance in Plasmodium falciparum
  162. Plasmodium falciparum Founder Populations in Western Cambodia Have Reduced Artemisinin SensitivityIn Vitro
  163. Acute Undifferentiated Febrile Illness in Rural Cambodia: A 3-Year Prospective Observational Study
  164. Patterns of selection onPlasmodium falciparumerythrocyte-binding antigens after the colonization of the New World
  165. Genomic analyses of complex P. vivax infections
  166. Limited polymorphisms in k13 gene in Plasmodium falciparum isolates from Dakar, Senegal in 2012–2013
  167. Plasmodium prevalence and artemisinin-resistant falciparum malaria in Preah Vihear Province, Cambodia: a cross-sectional population-based study
  168. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria
  169. De Novo Assembly of a Field Isolate Genome Reveals Novel Plasmodium vivax Erythrocyte Invasion Genes
  170. Global analysis of Plasmodium falciparum Na+/H+ exchanger (pfnhe-1) allele polymorphism and its usefulness as a marker of in vitro resistance to quinine
  171. Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies
  172. Whole Genome Sequencing of Field Isolates Reveals a Common Duplication of the Duffy Binding Protein Gene in Malagasy Plasmodium vivax Strains
  173. Injections, Cocktails and Diviners: Therapeutic Flexibility in the Context of Malaria Elimination and Drug Resistance in Northeast Cambodia
  174. G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests
  175. Therapeutic efficacy of fixed dose artesunate-mefloquine for the treatment of acute, uncomplicated Plasmodium falciparum malaria in Kampong Speu, Cambodia
  176. Ex VivoSusceptibility of Plasmodium falciparum to Antimalarial Drugs in Western, Northern, and Eastern Cambodia, 2011-2012: Association with Molecular Markers
  177. The Evolutionary History of Plasmodium vivax as Inferred from Mitochondrial Genomes: Parasite Genetic Diversity in the Americas
  178. Étude de la résistance dePlasmodium falciparumaux antipaludiques au sein du réseau international des Instituts Pasteur (RIIP-Palu)
  179. In SilicoScreening on the Three-dimensional Model of thePlasmodium vivaxSUB1 Protease Leads to the Validation of a Novel Anti-parasite Compound
  180. High-Throughput Analysis of Antimalarial Susceptibility Data by the WorldWide Antimalarial Resistance Network (WWARN)In VitroAnalysis and Reporting Tool
  181. Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report
  182. Efficacy of the antimalarial drugs recommended by the National Malaria Control Programme in Madagascar
  183. Plasmodium falciparum Na+/H+ Exchanger (pfnhe-1) Genetic Polymorphism in Indian Ocean Malaria-Endemic Areas
  184. An innovative tool for moving malaria PCR detection of parasite reservoir into the field
  185. G6PD deficiency in Plasmodium falciparum and Plasmodium vivax malaria-infected Cambodian patients
  186. Efficacy of Dihydroartemisinin-Piperaquine for Treatment of Uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010
  187. Reduced Artemisinin Susceptibility of Plasmodium falciparum Ring Stages in Western Cambodia
  188. Effect of High-Dose or Split-Dose Artesunate on Parasite Clearance in Artemisinin-Resistant Falciparum Malaria
  189. Focused Screening and Treatment (FSAT): A PCR-Based Strategy to Detect Malaria Parasite Carriers and Contain Drug Resistant P. falciparum, Pailin, Cambodia
  190. Mapping the Aetiology of Non-Malarial Febrile Illness in Southeast Asia through a Systematic Review—Terra Incognita Impairing Treatment Policies
  191. Whole Genome Sequencing of Field Isolates Provides Robust Characterization of Genetic Diversity in Plasmodium vivax
  192. Management of uncomplicated malaria in febrile under five-year-old children by community health workers in Madagascar: reliability of malaria rapid diagnostic tests
  193. Compliance, Safety, and Effectiveness of Fixed-Dose Artesunate-Amodiaquine for Presumptive Treatment of Non-Severe Malaria in the Context of Home Management of Malaria in Madagascar
  194. Performance of “VIKIA Malaria Ag Pf/Pan” (IMACCESS®), a new malaria rapid diagnostic test for detection of symptomatic malaria infections
  195. Individual Plasmodium vivax msp1 Variants within Polyclonal P. vivax Infections Display Different Propensities for Relapse
  196. Multiple independent introductions of Plasmodium falciparum in South America
  197. Performance of the CareStart™ G6PD Deficiency Screening Test, a Point-of-Care Diagnostic for Primaquine Therapy Screening
  198. Reduced Impact of Pyrimethamine Drug Pressure on Plasmodium malariae Dihydrofolate Reductase Gene
  199. Plasmodium knowlesi Infection in Humans, Cambodia, 2007–2010
  200. In vitro susceptibility to pyrimethamine of DHFR I164L single mutant Plasmodium falciparum
  201. The global distribution of the Duffy blood group
  202. Chloroquine Clinical Failures in P. falciparum Malaria Are Associated with Mutant Pfmdr-1, Not Pfcrt in Madagascar
  203. Plasmodium vivax and the Duffy antigen: A paradigm revisited
  204. Heritability of the Human Infectious Reservoir of Malaria Parasites
  205. OPV strains circulation in HIV infected infants after National Immunisation Days in Bangui, Central African Republic
  206. Association of Microsatellite Variations of Plasmodium falciparum Na+/H+ Exchanger (Pfnhe-1) Gene with Reduced In Vitro Susceptibility to Quinine: Lack of Confirmation in Clinical Isolates from Africa
  207. Origins of the Recent Emergence of Plasmodium falciparum Pyrimethamine Resistance Alleles in Madagascar
  208. Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy people
  209. Global sequence variation in the histidine-rich proteins 2 and 3 of Plasmodium falciparum: implications for the performance of malaria rapid diagnostic tests
  210. History and current status of Plasmodium falciparum antimalarial drug resistance in Madagascar
  211. Plasmodium falciparum Drug Resistance in Madagascar: Facing the Spread of Unusual pfdhfr and pfmdr-1 Haplotypes and the Decrease of Dihydroartemisinin Susceptibility
  212. Epidemiological situation of malaria in Madagascar: Baseline data for monitoring the impact of malaria control programmes using serological markers
  213. Rapid detection of point mutations in Plasmodium falciparum genes associated with antimalarial drugs resistance by using High-Resolution Melting analysis
  214. High Prevalence and Fixation of Plasmodium vivax dhfr/dhps Mutations Related to Sulfadoxine/Pyrimethamine Resistance in French Guiana
  215. Low Efficacy of Vocamine (MMH8®, Pediatric Formulation) in the Treatment of Uncomplicated Plasmodium falciparum Malaria
  216. Analysis of circulating populations ofPlasmodium falciparumin mild and severe malaria in two different epidemiological patterns in Madagascar
  217. Evaluation of Two New Immunochromatographic Assays for Diagnosis of Malaria
  218. Plasmodium vivax Resistance to Chloroquine in Madagascar: Clinical Efficacy and Polymorphisms in pvmdr1 and pvcrt-o Genes
  219. Dihydrofolate Reductase I164L Mutation inPlasmodium falciparum, Madagascar
  220. Assessment of the efficacy of antimalarial drugs recommended by the National Malaria Control Programme in Madagascar: Up-dated baseline data from randomized and multi-site clinical trials
  221. Performance and reliability of the SYBR Green I based assay for the routine monitoring of susceptibility of Plasmodium falciparum clinical isolates
  222. Plasmodium vivax dhfr and dhps mutations in isolates from Madagascar and therapeutic response to sulphadoxine-pyrimethamine
  223. Accuracy and Reliability of Malaria Diagnostic Techniques for Guiding Febrile Outpatient Treatment in Malaria-Endemic Countries
  224. Genetic diversity and genotype multiplicity of Plasmodium falciparum infections in symptomatic individuals living in Bangui (CAR)
  225. Country-wide assessment of the genetic polymorphism in Plasmodium falciparum and Plasmodium vivax antigens detected with rapid diagnostic tests for malaria
  226. Molecular epidemiology of wild poliovirus type 1 circulation in West and Central Africa, from 1997 to 1999, using genotyping with a restriction fragment length polymorphism assay
  227. Prevalence and Chloroquine Sensitivity of Plasmodium malariae in Madagascar
  228. Drug-Resistant Malaria Parasites Introduced into Madagascar from Comoros Islands
  229. Randomized clinical trial of artemisinin versus non-artemisinin combination therapy for uncomplicated falciparum malaria in Madagascar
  230. WHICH MALARIA RAPID TEST FOR MADAGASCAR? FIELD AND LABORATORY EVALUATION OF THREE TESTS AND EXPERT MICROSCOPY OF SAMPLES FROM SUSPECTED MALARIA PATIENTS IN MADAGASCAR
  231. Sequence analysis of Plasmodium falciparum cytochrome b in multiple geographic sites
  232. POLYMORPHISMS IN PFCRT, PFMDR1, DHFR GENES AND IN VITRO RESPONSES TO ANTIMALARIALS IN PLASMODIUM FALCIPARUM ISOLATES FROM BANGUI, CENTRAL AFRICAN REPUBLIC
  233. Efficacy of chloroquine–proguanil malaria prophylaxis in a non-immune population in Bangui, Central African Republic: a case–control study
  234. FREQUENCY DISTRIBUTION OF ANTIMALARIAL DRUG-RESISTANT ALLELES AMONG ISOLATES OF PLASMODIUM FALCIPARUM IN BANGUI, CENTRAL AFRICAN REPUBLIC
  235. Cocirculation of measles virus genotype B2 and B3.1 in Central African Republic during the 2000 measles epidemic
  236. Wild Poliovirus Type 1, Central African Republic
  237. ASSOCIATION OF FAILURES OF SEVEN-DAY COURSES OF ARTESUNATE IN A NON-IMMUNE POPULATION IN BANGUI, CENTRAL AFRICAN REPUBLIC WITH DECREASED SENSITIVITY OF PLASMODIUM FALCIPARUM
  238. DRUG-RESISTANT MALARIA IN BANGUI, CENTRAL AFRICAN REPUBLIC: AN IN VITRO ASSESSMENT
  239. Evaluation of rapid HIV testing strategies in under equipped laboratories in the Central African Republic
  240. EFFICACY OF CHLOROQUINE, AMODIAQUINE, SULFADOXINE-PYRIMETHAMINE, CHLOROQUINE-SULFADOXINE-PYRIMETHAMINE COMBINATION, AND AMODIAQUINE-SULFADOXINE-PYRIMETHAMINE COMBINATION IN CENTRAL AFRICAN CHILDREN WITH NONCOMPLICATED MALARIA
  241. HIV epidemic in central african republic: High prevalence rates in both rural and urban areas
  242. Advantages of an alternative strategy based on consecutive HIV serological tests for detection of HIV antibodies in Central African Republic
  243. Immunohematological Reference Ranges for Adults from the Central African Republic
  244. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in Bangui, Central African Republic
  245. Extrapulmonary and Pulmonary Tuberculosis in Antananarivo (Madagascar): High Clustering Rate in Female Patients
  246. Transmission of tuberculosis in the prison of Antananarivo (Madagascar)